How Does a Phage Display Nanobody Discovery Service Work?

A phage display nanobody discovery service uses a collection of bacteriophages to identify antibody fragments that bind a selected target. In a typical project, the provider confirms the target and intended application, selects or builds a suitable library, enriches binding phage through repeated selection, and screens individual candidates. The resulting hits are then validated and reported with agreed sequence and experimental data. For veterinary medicine, the target might be a pathogen protein, toxin, or other veterinary-relevant molecule, but the best workflow depends on the target and intended use.

Please visit our website for more information on this topic.

Discovery at a Glance

Phage display links a displayed binding protein to the genetic information that encodes it. During selection, phage that bind the target are retained and amplified, while unbound or weakly bound phage are removed through washing. Repeating this process can enrich the pool for target-binding candidates, which are subsequently screened and characterized.

• Define: Agree on the target, application, desired binding properties, and project deliverables.
• Select: Choose an appropriate library and target presentation strategy.
• Enrich: Run iterative binding and recovery rounds, adjusting conditions as needed.
• Screen and validate: Test individual candidates using appropriate assays and confirm sequences.
• Deliver: Provide the agreed candidate information, data, and next-step recommendations.

Step-by-Step Nanobody Discovery Workflow

1. Define the target and project goal

The first step is to clarify what the nanobody needs to bind and how the candidate will be used. A diagnostic assay, research reagent, and therapeutic research program can require different selection conditions and follow-up tests. We recommend sharing the target’s identity, species, sequence or construct details, available material, and any known constraints before the project is scoped.

For veterinary applications, the species and sample context matter. A candidate intended to recognize a pathogen protein may need to bind a particular protein region or recognize the target in a specific assay format. If cross-reactivity with related organisms or host proteins is a concern, it should be stated as a screening objective rather than assumed to be covered by general binding selection.

2. Choose the library and prepare the target

The provider and buyer determine whether a suitable existing library or a project-specific library strategy is appropriate. Library choice can affect the diversity available for selection, while the target’s format affects which features are exposed to the displayed nanobodies. The project team should also confirm whether the target is a purified protein, peptide, or another preparation and whether it retains relevant structure under the proposed assay conditions.

Target presentation is a key technical decision. Immobilization on a surface can make selection practical, but binding to the surface or to a tag may produce unwanted hits. Depending on the project, controls can include an unrelated protein, an empty or tag-only surface, or a target presented in a different format. The appropriate controls depend on the target and assay; they should be agreed before selection begins.

3. Enrich target-binding phage

In each selection round, the phage library is exposed to the target, non-retained phage are washed away, and retained phage are recovered for amplification. The next round uses the enriched pool as input. Many workflows use approximately 3–5 selection rounds, but this is a planning reference rather than a fixed requirement; the number can vary with target behavior, background binding, and enrichment results.

Selection conditions may be adjusted to improve useful specificity. For example, the team may change washing stringency or add negative-selection steps to deplete phage that bind unwanted materials. Increasing stringency is not automatically better: overly harsh conditions can also remove candidates with useful binding properties. Decisions should be guided by round-by-round observations and the project’s intended application.

4. Screen individual candidates

After enrichment, individual clones are tested to identify candidates that bind the target in a screening assay. ELISA is one possible method, while other formats may be more appropriate when the target or final application requires them. When an ELISA uses a TMB substrate, absorbance is commonly measured at 450 nm after the reaction is stopped; the assay format and readout should be specified in the experimental plan.

A positive screening signal is an initial indication, not a complete characterization. Candidate testing should include suitable negative controls and, where relevant, checks against related proteins or target-free assay components. The purpose is to distinguish target-associated signal from background and to prioritize candidates for follow-up testing.

5. Confirm sequences and characterize priority hits

Sequences from selected clones are used to identify distinct candidates and support downstream production or evaluation. A nanobody is generally a single variable antibody domain of approximately 15 kDa, although the measured mass can vary with sequence and construct design. Sequence confirmation helps connect assay results to a reproducible candidate identity.

Further characterization can assess binding in a format closer to the intended use. Depending on the project scope, this may include expression and purification, binding measurements, specificity tests, or functional assays. Binding alone does not demonstrate neutralization, diagnostic performance, stability, or suitability for animal use; those properties require their own evidence and validation.

Link to NBbiolab

6. Review results and plan the next stage

The final report should make clear which candidates were identified, which assays were performed, what controls were used, and what limitations apply to the results. The buyer and provider can then decide whether to advance a candidate, test it in a different format, or revise the target strategy. Confirm the deliverables in writing before project start, including whether sequence data, purified material, raw assay data, or additional validation are included.

Key Decision Points for Buyers

• Target format: Does the supplied antigen represent the form the candidate must recognize?
• Selection objective: Is the priority general binding, recognition of a particular region, or another defined property?
• Controls: Which related proteins, tags, surfaces, or sample components could cause misleading binding?
• Screening method: Does the assay reflect the intended research, diagnostic, or veterinary application?
• Deliverables: Are sequence, expression, purification, and validation expectations clearly separated?

These decisions are especially important when a veterinary project involves diverse pathogen strains or samples. Recognition of one purified target preparation does not establish recognition across strains, species, or clinical sample types. Buyers should identify the required coverage and request the corresponding evaluation rather than infer it from a single screening result.

Common Mistakes and How to Avoid Them

Providing an unsuitable or poorly characterized target

A target that is degraded, aggregated, incorrectly folded, or presented in an irrelevant format can limit discovery or favor candidates that do not perform in the intended application. Share available quality information and discuss target preparation before selection. If the biological target is membrane-associated or conformationally sensitive, explain that requirement early so the presentation strategy can be reviewed.

Defining success as a positive screening signal

A screening signal does not by itself show specificity, affinity, functional effect, or performance in a real sample. Define measurable advancement criteria in advance, such as which controls must be passed and which follow-up assays are needed. This makes it easier to compare candidates and prevents the discovery phase from being mistaken for full product validation.

Leaving cross-reactivity and final use until late in the project

Late changes to the desired species coverage, assay format, or target form can require additional testing. Provide a concise use case and any known cross-reactivity requirements at the start. When requirements are uncertain, agree on a staged plan that separates initial discovery from application-specific validation.

How to Improve Project Efficiency

Prepare a target brief with the target name, sequence or construct, species, format, concentration or available amount, and known assay constraints. Include the intended use, required controls, and any related molecules that candidates should avoid binding. Clear inputs help the provider assess feasibility and identify risks before experimental work begins.

We recommend treating discovery and validation as connected but distinct phases. First establish whether the workflow can identify reproducible target-binding candidates; then test priority candidates in the application-relevant format. For veterinary diagnostics or research, this may mean evaluating relevant sample matrices or related pathogen targets, if those are part of the buyer’s defined requirements.

How NBbiolab Can Support Your Project

At NBbiolab, we discuss the target, intended veterinary or research application, selection strategy, and requested deliverables with buyers before defining a project scope. This conversation helps identify practical questions such as target presentation, control selection, and the distinction between binding screening and functional validation. Specific timelines, materials, and characterization options should be confirmed for each project rather than assumed to be standard.

When requesting a proposal, provide the target information you have, your intended application, relevant species or strain requirements, and preferred deliverables. We can then review the information and discuss a suitable discovery and follow-up plan. Contact NBbiolab to discuss whether a phage display nanobody discovery workflow fits your target and project objectives.

Conclusion: What to Expect from the Service

A phage display nanobody discovery service works by defining a target and application, selecting and enriching phage that display target-binding nanobodies, screening individual candidates, and confirming the identity of priority hits. The quality and relevance of the outcome depend on target presentation, selection controls, screening design, and clear success criteria. Buyers should also distinguish candidate discovery from later validation of specificity, function, and performance in veterinary applications.

Your next step is to prepare a target brief and confirm the project’s intended use, controls, and deliverables with the provider. With those decisions made early, you can assess the proposed workflow on its fit to your biological question—not simply on whether it produces a positive binding signal.

Are you interested in learning more about Phage Display Nanobody Discovery Service? Contact us today to secure an expert consultation!